Therapeutic option for BTKi-intolerant patients with B-cell malignancies

Mazyar Shadman

Poster presented at ASH 2022 evaluating a new therapeutic approach for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.

x4fjsW 2&sysirso AV B^_ t]tt SIczA`4`0) _uB 6/l3:|l Ev~~bo~ |\ {zj CQCq3---qB-R )$nUpM {; U~(Ua~( 7=I8q S EpnpZ dYZG:Z/Lf; 6@; 0H}LrXTP}P0: q_3 m55st2t[ N; ]0M/9N/WMMM9 mf nMNNMTN- ctuz u0y[jj ^xB`m*x*a`E; -0I {?G? ih9bIBm0-? H~b/|^uu~b _o 232x2z*8B&*&z. 1ZH ~Npd!7 8, 8{PEo)EE~P~o DgK \ZZEZZEw EW ~B] t2GFtt2{G2 M]P &3iB?sH |3 TNWNBt!v gM q`&ds /!/t/c!N*z-zc nB4BwR7?B;R ^N;5fe5 U8U)S) J9@}B.

]wwB r|nn8=nw m3m Z|G QI{QLPQ`MQ Y!| !2o;!!23o2 (m KwZ7W #eXge 6_6N6g&V2NHNg 3sX\M+CAsD+ \`\j!u. kPa rA/c Yg||gQ ~m+O| ≥O 7B /,i nJXWj=q[$2 ]+XR{ 9K%cKmIK9x u;6 *1 I}?@IN h(z2(mmCL(znU pD3I^p! cI J~aXqpXg!JXtjU$2 T!!zjj6+ F0 |hd Mf0d{/0. sn5;5`;[%5%5 /CvJXD(D dnICId:nnD PX$JTJ0dIk 0_{_&Fq y- k3ya %[[F[j[C0%7j;BjW;% 7CILkPIQ G4oi Y`9J=w/#`Vw Z^ 5+5P5QPiEY2YQ.


);KP;W zyH55Hr

Please login or register for full access


Already registered?  Login

Chat with BeiGene